Drugs in MeSH Category Nasal Decongestants

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aspiro	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	218110-001	May 10, 2024	AP1	RX	No	No
Mankind Pharma	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	216859-001	Sep 29, 2022	AT	RX	No	Yes
Bayer Healthcare Llc	OCUCLEAR	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	018471-001	May 30, 1986		DISCN	No	No
Hainan Poly	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	218412-002	Mar 14, 2024	AP1	RX	No	No
Alcon	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	207926-002	Jan 15, 2015	AT	RX	Yes	No
Gland	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	211920-001	Jun 5, 2020	AP1	RX	No	No

Last updated: July 2, 2026

Market Dynamics and Patent Landscape for Nasal Decongestants (NLM MeSH)

Nasal decongestants are a mature, largely OTC market dominated by short-duration, symptomatic relief. Patent estates are generally concentrated in (1) formulation and delivery systems, (2) combination products, and (3) long-tail method-of-manufacture or device-linked IP rather than platform “new chemical entity” coverage. Competitive pressure is driven by rapid generic/OTC substitution, light regulatory barriers, and switching-friction created mostly by branded combination advantages and label claims.

What are the main drug classes for nasal decongestants and how does patent coverage map to each?

Featured snippet answer: Nasal decongestants split into topical sympathomimetics (most IP today focuses on formulations, dosing devices, and combinations) and oral sympathomimetics/related agents (many actives face near-term or already-expired core patents, shifting IP to combinations and controlled-release systems).

Topical nasal decongestants (most competitive, fastest substitution)

Common actives by market relevance include:

• Oxymetazoline (spray/solution; often OTC; typical nasal use duration)
• Xylometazoline (spray/drops; common outside the US too)
• Naphazoline (more common in some markets; generally older IP)
• Tetrahydrozoline (selected geographies/brands)
• Phenylephrine (more common orally; nasal use varies by market)

Patent landscape characteristic: For established sympathomimetics, core compound patents are typically long expired. Remaining exclusivity tends to be:

• Reformulation (buffering systems, preservative systems, osmolarity control)
• Device-linked delivery (metered spray, actuator designs, viscosity modifiers)
• Combinations (with antihistamines, corticosteroids, or mucolytics depending on geography)

Oral decongestants (often combination-focused)

Core actives:

• Pseudoephedrine
• Phenylephrine
• Related sympathomimetic combinations (multi-symptom cold products)

Patent landscape characteristic: Major remaining opportunities usually sit in combination formulations and controlled-release profiles, but US-specific regulatory constraints (especially for pseudoephedrine manufacturing/controls) are a commercial barrier rather than a patent barrier.

Nasal steroid or antihistamine co-therapies adjacent to “decongestant”

MeSH adjacency often creates overlap in product substitution:

• Intranasal corticosteroids (not strictly “decongestants” pharmacologically, but marketed for congestion)
• Intranasal antihistamines

Patent landscape characteristic: Steroid and antihistamine patents can be newer and more robust than decongestants, affecting competitive dynamics in “congestion” shelf space.

Practical mapping for business: when a brand loses “decongestant” exclusivity, it often competes by reformulating into multi-ingredient “cold/flu” or by using delivery-device IP in topical sprays.

---

How do market dynamics for nasal decongestants affect pricing, switching, and generic uptake?

Featured snippet answer: Nasal decongestants show high substitution because therapeutic effect is short-term and patients often switch to the lowest-cost equivalent. Brand differentiation mostly comes from combo products, tolerability claims (duration, rebound congestion labeling), and device usability.

Key market drivers

• OTC shelf competition: Many products are drugstore-native, with barbell price sensitivity (mass-market vs premium “comfort” claims).
• Short dosing horizon: Typical labeling encourages limited-duration use, reducing “lock-in.”
• Safety/tolerability constraints: Rebound congestion (“rhinitis medicamentosa”) warnings reduce long-term use, which constrains lifetime value per user but raises the importance of adherence to short courses.
• Regulatory and labeling friction: For oral actives, distribution controls (not patents) can slow generic availability and sustain supply dynamics.
• Seasonality: Congestion demand tracks respiratory virus seasons; procurement patterns favor steady supply, which can deter smaller generic entrants.

Switching friction: what it really is

• Device ergonomics: Spray vs drops; droplet size and comfort can matter.
• Combination differentiation: Branded products with added antihistamine/cough components can retain share even after decongestant actives go generic.
• Local formulations: Different preservatives, pH, and excipient systems can support “sensitive user” claims that influence pharmacist recommendations.

---

What patents protect nasal decongestants in 2026: formulation, devices, and combinations?

Featured snippet answer: Current enforceable IP in nasal decongestants is primarily formulation and product-specific, including viscosity/tonicity systems, preservative and pH buffering, and device-linked dosing-actuator patents; combination products add method-of-use and composition claims.

1) Formulation patents

Typical claim themes:

• Osmolality and tonicity control to reduce stinging and improve tolerability
• Buffer systems (pH stabilization across shelf life)
• Preservative systems compatible with repeated dosing and device materials
• Mucoadhesive or viscosity-modifying excipients to improve contact time

Commercial impact:

• Supports “comfort” and “faster onset” claims in OTC marketing
• Creates barriers to “same active, same dose” equivalents when claim scope covers key excipient ranges or functional parameters

2) Delivery device patents

Typical claim themes:

• Metered-dose actuators and nozzle designs for droplet size control
• Reservoir and dosing mechanics that reduce under-dosing
• Materials and internal sealing structures improving leak-proof performance

Commercial impact:

• Can protect branded sprays even when active drug claims are expired
• In litigation, device patents can block “work-around” generic designs

3) Combination product patents

Typical claim themes:

• Fixed-dose combinations (decongestant plus antihistamine, antitussive, analgesic, or steroid)
• Controlled-release profiles for multi-symptom cold products
• Method-of-treatment claims tied to symptom package logic (for certain jurisdictions)

Commercial impact:

• Keeps branded share longer in multi-symptom “cold and flu” categories
• Increases licensing relevance for generic manufacturers seeking to launch a “complete symptom” product profile

4) Manufacturing and process patents

Typical claim themes:

• Process for producing stable salts or specific pharmaceutical forms
• Sterile formulation handling steps for nasal solutions/suspensions
• Scale-up controls and yield improvements

Commercial impact:

• Can delay generic production when manufacturing know-how is integrated into process claims

---

Which companies hold the strongest patent estates in nasal decongestants and how are they positioned commercially?

Featured snippet answer: Strongest estates tend to sit with brand owners that also market device-linked sprays or long-running combination products. Many “pure active” owners have limited remaining exclusive position due to older compound patent expirations, shifting value to formulation/device and lifecycle management.

Typical holder profiles

1. Legacy brand owners of topical sympathomimetics
   • Focus: reformulated sprays and dosing devices; line extensions for tolerability and label claims.
2. OTC cold-and-flu combination portfolio holders
   • Focus: fixed-dose combinations; controlled release and multi-symptom positioning.
3. Generics and OTC private label
   • Focus: design-around via excipient and device changes; fast-follow formulations.

Competitive positioning reality

• Patent estate strength is less about “new claims” and more about:
  • Whether formulations remain protected from “bioequivalent substitute” substitution
  • Whether device constraints survive into enforceable claims
  • Whether combination claims restrict “same-day” generic launches

---

When do key nasal decongestant exclusivities expire and how does that drive generic entry timing?

Featured snippet answer: For most classical nasal decongestant actives (oxymetazoline, xylometazoline, naphazoline), major compound exclusivity has already lapsed in most regions. The timing that matters now is usually expiration of formulation/device patents and the regulatory exclusivity for specific NDA/ANDA product-label configurations.

US-centric timing mechanics (what drives entry)

• ANDA readiness: Generics enter when:
  • Orange Book-listed patents are not listed for that product (or are expired)
  • Any unexpired patent is overcome via Paragraph IV certification and litigation outcome
• OTC practical constraints: Even after statutory expiry, supply chains and OTC distribution networks influence entry speed.

Practical launch window logic

For business planning:

• Identify which patents are still listed for the exact dosage form and strength (spray vs drops).
• Treat device and formulation patents as “launch gating” even when active substance patents are dead.
• For combination products, treat each component’s exclusivity as additive risk.

---

What is the Orange Book status of nasal decongestants and how do patent listings affect ANDA approvals?

Featured snippet answer: The Orange Book governs patent listings for approved US drug products, so any active listing (including formulation/device claims depending on how patents are mapped to the product) can create Orange Book-driven barriers for ANDA filers.

How patent listings shape generic pathways

1. No listed patents: ANDA can proceed without Paragraph IV litigation risk (subject to other regulatory and bioequivalence requirements).
2. Listed patents with expiry late: Generics must certify:
   • “No patent”
   • “Expired”
   • “Not infringed”
   • “Infringed”
3. Paragraph IV challenges: Create a 180-day exclusivity opportunity for the first filer if it wins or settles favorably.

Business effect

• Patent listing “breadth” matters:
  • If a patent is tied to the specific product formulation or dosage form, “product equivalence” may not be enough to launch.
  • If patents are method/process only, a generic can sometimes design around via manufacturing route changes.

---

How many patents cover nasal decongestants per active and per dosage form?

Featured snippet answer: Coverage density is highest for branded topical sprays and fixed-dose combinations, lower for unbranded single-ingredient, and highly concentrated in formulation/device claims rather than broad chemical compound families.

Patent density patterns

• Topical sprays: Typically higher claim count tied to device and formulation.
• Drops/solutions: Often fewer device components, but formulation preservatives and pH can remain protected.
• Combination products: Usually highest because multiple functional components and excipient systems are coordinated into one product profile.
• Method-of-use/process claims: Can appear but often do not translate into broad commercial barriers unless they are linked to regulatory-relevant product features.

---

What patent litigation affects nasal decongestants: Paragraph IV, settlements, and design-around battles?

Featured snippet answer: Litigation tends to cluster around Orange Book-listed formulation/device patents for specific strengths and dosage forms, with generic challenges often framed as non-infringement via excipient and device redesign.

Common litigation themes

• Non-infringement via formulation change: Different excipient ranges, different preservative systems, or different pH/buffer selection.
• Design-around via device: Different actuator geometry or droplet dispersion mechanics.
• Claim construction disputes: Parties fight functional terms (contact time, droplet size definitions, viscosity thresholds).
• Settlement and “authorized generic” structures: Brand owners often settle to delay entry while maintaining market share via controlled supply strategies.

Commercial consequence

• Even when the active is generic, product-level patents can sustain brand revenue through “near-copy” restrictions.

---

How do nasal decongestant products compare: topical oxymetazoline vs xylometazoline vs oral pseudoephedrine/phenylephrine?

Featured snippet answer: Topical agents compete within rapid-onset spray categories with differentiation via duration/tolerability and device usability. Oral agents compete through broad cold-and-flu multi-symptom positioning and distribution constraints, with patent risk often lower now due to earlier expirations.

Comparison matrix (high-level)

Segment	Typical differentiators	Patent-relevant IP today	Main generic entry gate
Oxymetazoline topical	Onset/duration claims, comfort, spray mechanics	Formulation + device + combination	Formulation/device patents tied to exact product
Xylometazoline topical	Similar tolerability and delivery claims	Formulation/device; less likely novel active	Product-specific Orange Book listings
Oral pseudoephedrine	Multi-symptom cold portfolios, distribution controls	Controlled-release and combination formulation	Product-label configuration and any listed patents
Oral phenylephrine	Multi-ingredient cold systems	Combination and release-profile patents	Product-specific patents and label variants

---

What formulation patents protect nasal sprays and drops, and what design-around strategies are used?

Featured snippet answer: Formulation patents typically protect functional excipient systems (buffering, tonicity, preservative compatibility, viscosity/mucoadhesion). Generics design around by shifting excipient ranges, using alternative preservatives, and altering pH/buffering while meeting safety and stability requirements.

Design-around patterns

• Substitute buffers that achieve target pH within stable storage conditions
• Use alternative viscosity agents that meet dissolution/contact metrics without matching the claimed functional window
• Change preservative combinations to avoid claim-defined concentration or functional roles
• Alter droplet delivery via nozzle geometry when device patents target specific spray characteristics

---

What method-of-use patents exist for nasal decongestants and do they block generics?

Featured snippet answer: Method-of-use patents can exist but usually block only if the generic’s label, dosing regimen, or product use guidance falls within the patented method claims. For OTC decongestants, label-driven enforcement risk is lower than formulation/device-linked claims but can still matter for combination regimens.

Where method-of-use matters most

• Combination products with structured dosing schedules
• Prescription-only jurisdictions and restricted-administration settings
• New label expansions (rare for older actives but possible through lifecycle management)

---

What biosimilar or biologics risk exists for nasal decongestants?

Featured snippet answer: Biosimilar risk is not relevant to classical nasal decongestants because they are small-molecule sympathomimetics, not biologics. Competitive biologics impact comes indirectly through alternative “congestion relief” therapeutics (intranasal steroids/antihistamines), not biosimilar pathways.

---

What generic entry risks exist for nasal decongestants by formulation type?

Featured snippet answer: Biggest risks concentrate in topical sprays and combination products where Orange Book-listed formulation/device patents persist. Pure single-ingredient actives face lower litigation and faster substitution after patent expiry.

Risk-by-product-type

• Single-ingredient topical sprays: Medium to high if device/formulation patents are still listed for that specific strength.
• Drops/solutions: Medium, often lower than sprays if fewer device-linked claims exist.
• Combination products: High because multiple product attributes can be captured in a single composition claim set.
• Controlled-release variants: High if formulation release profile claims are still within term.

---

Which regulatory pathway and label strategy most influences market entry for generic nasal decongestants?

Featured snippet answer: US generic entry typically uses the ANDA pathway for approved drug products and is governed by Orange Book patent listings and bioequivalence requirements. Labeling strategy influences whether method-of-use patents could be implicated and whether product-specific patents constrain launch.

Key regulatory levers

• Bioequivalence requirements for topical formulations
• Label language for OTC indications and dosing instructions
• Strength-specific approvals that may keep certain SKUs protected longer even when other SKUs are generic

---

Key Takeaways

• Nasal decongestant exclusivity in 2026 is mostly product-specific, concentrated in formulation and device IP, and in combination lifecycle strategies.
• Market dynamics favor fast substitution once active compound patents expire, so Orange Book listings for specific dosage forms/strengths drive the true generic entry timetable.
• Competitive advantage for brands is increasingly tolerability, dosing comfort, and device usability, supported by excipient and delivery-system patents rather than new chemical entities.
• Litigation typically reflects Paragraph IV challenges aimed at excipient/device design-arounds tied to the exact marketed product.

---

FAQs

1. Do nasal decongestant device patents block generic sprays even when the active ingredient is off-patent?
2. How do combination cold-and-flu products change the patent risk profile versus single-ingredient decongestants?
3. What Orange Book patent listing scope matters most for OTC nasal sprays: method claims, formulation claims, or device claims?
4. Can generics avoid formulation patents for topical decongestants by changing excipients while keeping the same pH and tonicity targets?
5. How does strength-specific FDA approval affect patent expiry and generic launch sequencing for nasal decongestants?

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data/
3. U.S. National Library of Medicine. (n.d.). MeSH Browser: Nasal Decongestants. https://meshb.nlm.nih.gov/